- Bioactive Compounds
- By Signaling Pathways
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- Compound Libraries
- Antibodies
- Bioreagents
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- Protein Assay
- Protein A/G Magnetic Beads for IP
- Anti-DYKDDDDK Tag magnetic beads
- Anti-DYKDDDDK Tag Affinity Gel
- Anti-Myc magnetic beads
- Anti-HA magnetic beads
- Poly DYKDDDDK Tag Peptide lyophilized powder
- Protease Inhibitor Cocktail
- Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO)
- Phosphatase Inhibitor Cocktail (2 Tubes, 100X)
- Cell Biology
- Cell Counting Kit-8 (CCK-8)
- Animal Experiment
- Mouse Direct PCR Kit (For Genotyping)
- New Products
- Contact Us
-
Australia
-
Austria
-
Belgium
-
Brazil
-
Canada
-
China
-
Czech Republic
-
Denmark
-
Finland
-
France
-
Germany
-
Greece
-
Hong Kong
-
Hungary
-
Iceland
-
India
-
Ireland
-
Israel
-
Italy
-
Japan
-
Korea
-
Luxembourg
-
Malaysia
-
Netherlands
-
New Zealand
-
Norway
-
Poland
-
Qatar
-
Romania
-
Saudi Arabia
-
Singapore
-
Spain
-
Sweden
-
Switzerland
-
Taiwan
-
Turkey
-
United Kingdom
-
United States
-
Other Countries
New Products
- PI3K/Akt/mTOR
- JAK/STAT
- Cell Cycle
- DNA Damage
- TGF-beta/smad
- GPCR & G Protein
- Protein Tyrosine Kinase
- Epigenetics
- NF-κB
- Metabolism
- Proteases
- Microbiology
- Apoptosis
- MAPK
- Angiogenesis
- Stem Cell & Wnt
- Ubiquitin
- Neuronal Signaling
- Others
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| E4765 | TYM-3-98 | TYM-3-98 is a selective inhibitor of PI3Kδ with an IC50 of 7.1 nM. It blocks the PI3Kδ/AKT signaling pathway, induces apoptosis in B-cell lymphomas, and effectively suppresses xenograft tumor growth in vivo. | Jun 27 2025 |
| E5889 | PI3K/Akt/mTOR-IN-2 | PI3K/Akt/mTOR-IN-2 is a specific inhibitor of the PI3K/Akt/mTOR signaling pathway. It exhibits an effective anti-cancer activity with IC50 value of 2.29 μM and can induce cancer cell cycle arrest and apoptosis. | May 07 2025 |
| F2877 | GSK3β + GSK3α Rabbit mAb | Apr 29 2025 | |
| E5815 | YB-3-17 | YB-3−17 is a dual-target compound that effectively and selectively inhibits mTOR with an IC50 of 0.22 nM, while promoting GSPT1 degradation with an IC50 of 5 nM, leading to substantial tumor growth inhibition both in vitro and in vivo. It also exhibits significant antiproliferative activity in glioblastoma models. | Apr 14 2025 |
| F2636 | Phospho-Akt1 (Ser 129) Rabbit mAb | Mar 27 2025 | |
| E5875 | LY294002 hydrochloride | LY294002 hydrochloride is a potent and specific inhibitor of PI3K with an IC50 of 0.5 μM, 0.97 μM, and 0.57 μM for P110α, P110β, P110δ, respectively. It also acts as a direct blocker of L-type Ca2+ channel with IC50 of 20 µM. | Mar 14 2025 |
| F2969 | VPS35 Rabbit mAb | Mar 03 2025 | |
| F2906 | MELK Rabbit mAb | Mar 03 2025 | |
| E4683 | PI3K/AKT-IN-1 | PI3K/AKT-IN-1 is a dual-acting inhibitor of PI3K/AKT pathway with an IC50 of 6.99 µM, 4.01 µM, and 3.36 µM, for PI3Kδ, PI3Kγ and AKT-1 respectively. It also induces S-phase cell cycle arrest, caspase-3-dependent apoptosis, exhibiting strong potential against breast cancer and leukemia. | Jan 09 2025 |
| F2584 | Phospho-mTOR (Ser 2448) Rabbit mAb | mTOR (phospho S2448),Phospho-mTOR (Ser2448),p-mTOR | Dec 31 2024 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| E6446 | SD-2301 | SD-2301 is a potent and selective PROTAC-based STAT3 degrader that targets the VHL–cullin 2 complex, enhancing dendritic cell function and anti-tumor immunity. It synergizes with anti-PD-L1 therapy to robustly suppress tumor growth in vivo. | Jul 07 2025 |
| E5866 | Cenacitinib | Cenacitinib is an orally potent and selective allosteric inhibitor of tyrosine kinase 2 (Tyk2). It exhibits significant efficacy and can be used in research for the treatment of moderate to severe psoriasis. | Jun 12 2025 |
| E5802 | SD-436 | SD-436 is a potent and selective PROTAC degrader of STAT3 with a DC50 of 0.5 μM. It induces complete and long-lasting tumor regression in leukemia and lymphoma xenograft models in mice. | Jun 11 2025 |
| E1990 | KT-333 | KT-333 is a first-in-class, potent, and selective heterobifunctional degrader of STAT3 that recruits the VHL E3 ligase for ubiquitin-proteasome-mediated degradation. It induces robust antitumor activity in preclinical models of ALK⁺ anaplastic large cell lymphoma (ALCL). | Jun 11 2025 |
| E4720 | Flonoltinib | Flonoltinib (JAK2/FLT3-IN-1) is a potent and selective dual inhibitor of JAK2 and FLT3, with IC50 of of 0.8, 1.4, and 15 nM against JAK2, JAK2V617F, and FLT3, respectively, in in vitro kinase assays. It also inhibits cell proliferation and induces G2/M cell cycle arrest and apoptosis in Hemophagocytic Lymphohistiocytosis (HLH) patients' CD8+T cells, CTLL2 cells, and RAW 264.7 cells. | May 09 2025 |
| F3388 | STAT6 (G4A20) Rabbit mAb | Apr 17 2025 | |
| F3253 | Phospho-STAT1 (Ser 727) (C14E15) Rabbit mAb | Apr 16 2025 | |
| E6051 | niclosamide ethanolamine | Niclosamide ethanolamine (Niclosamide-olamine, BAY2353 olamine) is a mild mitochondrial uncoupler, anthelmintic agent, and highly potent inhibitor of STAT3 signaling pathway with an IC50 of 0.25 μM. It improves insulin levels, body weight, and muscle wasting, inhibits artery constriction, suppresses PI3K-mTORC1 signaling to block fibroblast proliferation, inhibits TGF-β1-induced EMT and ECM accumulation via the mTORC1-4EBP1 axis, activates noncanonical autophagy to sensitize fibroblasts to apoptosis, and confers renoprotection in diabetic and adriamycin-induced nondiabetic kidney disease models. | Apr 08 2025 |
| F1048 | PIAS1 Rabbit mAb | Mar 30 2025 | |
| E8276 | Golidocitinib 1-hydroxy-2-naphthoate | Golidocitinib 1-hydroxy-2-naphthoate is a derivative of Golidocitinib, an oral, potent, selective inhibitor of Janus kinase 1 (JAK1) with an IC50 of 70 nM. It exhibits enhnaced antitumor activity and can be used for the treatment of cancer, including peripheral T cell lymphoma (PTCL). | Mar 26 2025 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| E8310 | Ribociclib succinate hydrate | Ribociclib succinate hydrate is an orally bioavailable and selective, inhibitor of both CDK4 and CDK6 with IC50 values of 10 nM and 39 nM, respectively. It exhibits anticancer activitiy and can be used in breast cancer, melanoma, liposarcoma, non–small cell lung cancer, and neuroblastoma therapy research. | Jul 01 2025 |
| E6405 | AZD0022 | AZD0022 is a potent, orally bioavailable, selective, reversible inhibitor of KRASG12D that drives robust pathway inhibition and anti-tumour activity in KRASG12D models. | Jun 16 2025 |
| E6406 | AMG 410 | AMG410 is a non-covalent, selective inhibitor of pan-KRAS with IC50 of 1–4 nM for KRAS G12D, G12V, and G13D. It binds both GDP- and GTP-bound KRAS with Kd of 1 nM and 22 nM, respectively. AMG410 inhibits KRAS signaling in a nucleotide cycling-independent manner. It also suppresses proliferation in KRAS-amplified wild-type tumor cells. | Jun 16 2025 |
| E8287 | YX0597 | YX0597 is a potent and selective CDK9 PROTAC degrader that reduces RNA polymerase II S2 phosphorylation and MCL1 expression in GA0518 and AGS cells. It effectively inhibits GEAC cell growth, including radiation-resistant tumors, and suppresses tumor proliferation, metastasis, and cancer stem cells. | Jun 09 2025 |
| E8295 | LY3499446 | LY3499446 (KRASG12C IN-13) is a potent inhibitor of KRAS G12C. It can be used in research on advanced solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). | Jun 08 2025 |
| E8303 | YJ9069 | YJ9069 is a potent, selective and orally bioavailable PROTAC degrader of CDK12/CDK13. It inhibits proliferation in prostate cancer cells by inducing gene-length-dependent transcriptional elongation defects, leading to DNA damage, cell-cycle arrest, and significant tumor growth suppression in vivo. | Jun 08 2025 |
| E1455 | BTX-A51 | BTX-A51 (Casein Kinase inhibitor A51) is a first-in-class oral and potent inhibitor of casein kinase 1α (CK1α) and cyclin dependent kinase (CDK7/9) with an IC50 of 17 nM for CK1α and Kd of 1.3 nM and 4 nM for CDK7 and CDK9, respectively. It induces apoptosis of leukemic cells by activating p53 and inhibiting expression of Mcl1 and can be used in Acute myeloid leukemia (AML) cancer research. | Jun 04 2025 |
| F3715 | PPP2R5D Rabbit mAb | May 27 2025 | |
| F3324 | TPD52 Rabbit mAb | May 27 2025 | |
| F3558 | Phospho-CDC2(Thr 161) Rabbit mAb | May 27 2025 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| F3208 | Nova1 Rabbit mAb | Jun 25 2025 | |
| E6402 | GSK4418959 | GSK4418959 is a non-covalent, reversible, selective and orally active inhibitor of WRN helicase. It inhibits ATPase and DNA unwinding functions in an ATP-competitive manner and can be a potential therapeutic agent that can be used for the study of microsatellite instability-high (MSI-H) cancer research. | Jun 16 2025 |
| E8280 | Ecubectedin | Ecubectedin (PM14) is a transcriptional inhibitor that forms DNA adducts, blocking RNA synthesis and the transcription of protein-coding genes. It also exhibits potent antiproliferative activity in human solid cancer models both in vitro and in vivo. | Jun 09 2025 |
| E8302 | YX968 | YX968 is a potent, rapid, and selective PROTAC dual degrader of HDAC3/8 with DC50 values of 1.7 nM and 6.1 nM, respectively. It promotes apoptosis and kills cancer cells with a high potency in vitro and can be used in cancer research. | Jun 08 2025 |
| E8306 | ABBV-969 Payload | ABBV-969 Payload is an agent-linker conjugate with a potent inhibitor of topoisomerase I and a linker designed for use in the antibody-drug conjugate (ADC) ABBV-969. It can be used in non-small cell lung cancer research. | Jun 08 2025 |
| E8292 | GEM144 | GEM144 is a potent and orally active dual inhibitor of DNA polymerase α (POLA1) and HDAC11 . It exhibits potent antiproliferative activity in vitro and antitumor efficacy in vivo by inducing p53 acetylation, p21 activation, G1/S cell cycle arrest, and apoptosis. | Jun 08 2025 |
| E5886 | FEN1-IN-1 | FEN1-IN-1 (Compound 1) is an inhibitor of Flap endonuclease 1 (FEN1), binding to its active site and inhibiting activity partly by coordinating with Mg²⁺ ions. By blocking FEN1, it initiates a DNA damage response, activating the ATM checkpoint pathway, histone H2AX phosphorylation, and FANCD2 ubiquitination in mammalian cells. | Jun 05 2025 |
| E5851 | T26 | T26( PARP1-IN-35) is a potent, selective, orally active, inhibitor of PARP1 capable of crossing the blood-brain barrier, with IC50 values of 0.2 nM. It exhibits significant antitumor efficacy and holds potential as a research treatment for breast cancer metastases. | May 21 2025 |
| F1006 | PAX5 Rabbit mAb | Apr 29 2025 | |
| E5842 | Nudifloramide | Nudifloramide (2PY, N-methyl-2-pyridone-5- carboxamide) is a pyridine derivative of nicotinamide that inhibits PARP-1 (poly (ADP-ribose) polymerase-1) activity in vitro, with an IC50 of 8 µM. | Apr 20 2025 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| F3678 | SARA Rabbit mAb | SARA | May 27 2025 |
| F2576 | GDNF Rabbit mAb | Apr 29 2025 | |
| F2206 | BMP2 Rabbit mAb | Apr 29 2025 | |
| F2851 | Smad3 (H20E2) Rabbit mAb | Apr 16 2025 | |
| F2846 | Phospho-Smad3 (Ser 423/Ser 425) Rabbit mAb | Phospho-Smad3 (Ser423/425),Smad3 (phospho S423 + S425), Smad5 (463/465), Smad1 (Ser 463/465), Smad2 (Ser 465/467)d5 (Se | Mar 27 2025 |
| E4798 | SRI-011381 hydrochloride | SRI-011381 hydrochloride is an agonist of the transforming growth factor-beta (TGF-β) signalling pathway and exhibits neuroprotective effects with the potential to treat Alzheimer's disease. It also increases fibronectin expression in the NIH‐3T3 cells stimulated by metformin. | Jan 12 2025 |
| E8084 | Trimethylamine N-oxide-d9 | Trimethylamine N-oxide-d9 is the deuterium labeled Trimethylamine N-oxide. Trimethylamine N-oxide is a gut microbe-dependent metabolite of dietary choline and other trimethylamine-containing nutrients. Trimethylamine N-oxide induces inflammation by activating the ROS/NLRP3 inflammasome. Trimethylamine N-oxide also accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis by activating the TGF-β/smad2 signaling pathway. | Dec 20 2024 |
| E7578 | (-)-Indolactam V | (-)-Indolactam V is a PKC activator, with Kis of 3.36 nM, 1.03 μM for η-CRD2 (PKCη surrogate peptide), γ-CRD2 (PKCγ surrogate peptide), and Kds of 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A), 213 nM (γ-C1B), and has antitumor activity. | Dec 20 2024 |
| E7637 | Phorbol 12,13-dibutyrate | Phorbol 12,13-dibutyrate (Phorbol dibutyrate) is a PKC activator and a potent skin tumor promoter. | Dec 20 2024 |
| F2875 | Phospho-SMAD1/ SMAD5/ SMAD9 (Ser 463/ Ser 465/ Ser 467) Rabbit mAb | Phospho-Smad1 (Ser463/465)/ Smad5 (Ser463/465)/ Smad9 (Ser465/467),SMAD1 + SMAD5 + SMAD9 (phospho S463 + S465 + S467) | Dec 19 2024 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| E1576 | LUNA18 | LUNA18 (Paluratide) is an orally bioavailable 11-mer cyclic peptide KRAS inhibitor for the intracellular tough target RAS. It binds to KRASG12D with a kd of 0.043 nM and blocks KRASG12D–SOS1 interaction at IC50 of < 2.2 nM. It also exhibits antiproliferative activity in KRAS-mutant cancer cell lines with an IC50 of 1.4 nM in AsPC-1 pancreatic cancer cells. | Jun 18 2025 |
| E6403 | RMC5127 | RMC5127 is a first-in-class, orally bioavailable mutant-selective tri-complex inhibitor of the GTP-bound (ON) form of RASG12V. It non-covalently binds to cyclophilin A (CypA), forming a binary complex that engages RASG12V(ON) to form a high-affinity tri-complex, sterically inhibiting RAS binding. It inhibits the RAS pathway in KRASG12V-mutant cancer cells, reducing proliferation, inducing apoptosis, and showing strong potential for use in RASG12V-mutated cancer research. | Jun 16 2025 |
| E6418 | MDL12330A | MDL12330A is an inhibitor of adenylyl cyclase that blocks vasopressin-induced short-circuit current (SCC). It also inhibits cAMP phosphodiesterase, which may mask its effect on adenylyl cyclase. | Jun 16 2025 |
| E5847 | olomorasib | Olomorasib (KRAS G12C inhibitor 19, LY3537982) is a potent and highly selective second-generation inhibitor of GDP-bound KRAS G12C, with the potential to treat patients with advanced solid tumors carrying the KRAS G12C mutation. | May 12 2025 |
| E6049 | Domperidone monomaleate | Domperidone monomaleate (R33812 monomaleate) is a potent antagonist of dopamine D2 receptor that acts as an antiemetic and prokinetic agent by targeting the chemoreceptor trigger zone and motor function of the stomach and small intestine. It also inhibits cardiac Na⁺ channels such as Nav1.5, suggesting a potential molecular mechanism for cardiovascular side effects like malignant arrhythmias. | Apr 14 2025 |
| F1206 | Phospho-PKA α/β/γ (catalytic subunit) (Thr 197) Rabbit mAb | Mar 27 2025 | |
| F2428 | GTPase HRAS Rabbit mAb | Mar 27 2025 | |
| F2783 | Prostaglandin E Receptor EP2/PTGER2 Rabbit mAb | Mar 03 2025 | |
| F2937 | GPCR RDC1/CXCR-7 Rabbit mAb | Mar 03 2025 | |
| F0588 | PKA C-α Rabbit mAb | Mar 03 2025 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| E5881 | Firmonertinib | Firmonertinib is an oral, brain-penetrant, mutant-selective inhibitor of EGFR. It targets a broad spectrum of EGFR mutations, including exon 20 insertions and the T790M resistance mutation. Firmonertinib is being developed as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions. | Jun 11 2025 |
| E8288 | YW-N-7 TFA | YW-N-7 TFA is a PROTAC that targets the inhibition and degradation of RET with a DC50 of 88 nM. It also exhibits antitumor activity in a KIF5B-RET-driven xenograft mouse model. | Jun 09 2025 |
| E1725 | T025 | T025 is as an orally available and potent inhibitor of Cdc2‐like kinases (CLKs) with an IC50s of 0.93 nM, 1 nM, 14 nM, 1.5 nM for CLK1, CLK2, CLK3, DYRK1B respectively. It exhibits anti‐tumor efficacy and can be used in MYC‐driven cancer research. | Jun 05 2025 |
| E4646 | Risvodetinib | Risvodetinib(IkT-148009) is a potent, orally active, selective and brain-penetrant inhibitor of c-Abl with an IC50 of 33 nM. It significantly reduces α-Syn levels, helping prevent neurodegeneration and supporting its use in Parkinson’s disease research. | Jun 05 2025 |
| F0749 | Phospho-EGF Receptor (Tyr 845) Rabbit mAb | Apr 13 2025 | |
| E1919 | Befotertinib mesylate | Befotertinib mesylate (D-0316 mesylate) is third-generation tyrosine kinase inhibitor (TKI) of EGFR . It can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC). | Apr 13 2025 |
| F3049 | VEGF Receptor 2 Rabbit mAb | CD309 (FLK1),Flk-1,VEGF Receptor 2,VEGFR-2 | Mar 28 2025 |
| F2167 | IRS2 Rabbit mAb | Mar 28 2025 | |
| E5912 | Asandeutertinib | Asandeutertinib (Osimertinib-d3, AZD-9291-d3) is an orally administered, ATP-competitive, irreversible, deuterated third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) and a deuterium-stabilized derivative of osimertinib, with the potential to treat advanced EGFR-mutated NSCLC. | Mar 24 2025 |
| E5906 | Sunvozertinib | Sunvozertinib (DZD9008) is an oral, potent, and selective inhibitor of ErbBs (EGFR or Her2), particularly mutant forms of ErbBs. It also inhibits EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, Her2 exon 20 YVMA, and EGFR WT A431, with IC50 values of 20.4 nM, 20.4 nM, 1.1 nM, 7.5 nM, and 80.4 nM, respectively. | Mar 21 2025 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| E5948 | PB94 | PB94 is a potent and selective inhibitor of HDAC11 with an IC50 of 108 nM and exhibits >40-fold selectivity over other HDAC isoforms. It ameliorates neuropathic pain in mouse models and can be radiolabeled with carbon-11 as [¹¹C]PB94 for PET imaging, demonstrating significant brain uptake and potential for in vivo imaging applications. | Jul 04 2025 |
| E5988 | SKLB-11A | SKLB-11A is a selective, first-in-class allosteric activator of SIRT3 that binds with a Kd of 4.7 μM and enhances its deacetylase activity with EC50 of 21.95 μM. It improves cardiac function and alleviates myocardial damage in vivo. | Jun 18 2025 |
| F3165 | CITED2 Rabbit mAb | CITED2,Cited-2 | Jun 16 2025 |
| E6080 | AUR1545 | AUR1545 is a potent and selective degrader of KAT2A and KAT2B. It exhibits an anti-proliferative effect and significantly inhibits tumor growth in an NCI-H1048 xenograft model. | Jun 11 2025 |
| E4678 | EZH2/HSP90-IN-29 | EZH2/HSP90-IN-29 is a potent dual inhibitor of EZH2 and HSP90, with IC50s of 6.29 nM and 60.1 nM, for EZH2 and HSP90, respectively, that induces M-phase cell cycle arrest, promotes apoptosis/necrosis-related gene expression, and inhibits ROS catabolism. It crosses the blood-brain barrier and can show potential as a tractable anti-GBM agent for glioblastoma research. | Jun 11 2025 |
| E8279 | SPA-10091-HCl | SPA-10091-HCl is a degrader of DOT1L that selectively degrades DOT1L protein through the nuclear ubiquitin-proteasome pathway, thereby suppressing H3K79 methylation in CRPC cells. It also inhibits DOT1L enzymatic activity with an IC50 of 0.87 μM, induces apoptosis, and significantly reduces tumor growth in vivo. | Jun 09 2025 |
| E8293 | YD54 | YD54 is a potent, selective and orally bioavailable PROTAC and a degrader of SMARCA2 with DC50 of 8.1 nM at 24 hours. It exhibits antitumor activity in SMARCA4-mutant lung cancer xenograft models and can be used in research on non-small cell lung cancer. | Jun 09 2025 |
| E8294 | YDR1 | YDR1 is a potent, selective and orally bioavailable Cereblon-based PROTAC and a degrader of SMARCA2 with DC50 of 60 nM at 48 hours. It exhibits antitumor activity in SMARCA4-mutant lung cancer xenograft models and can be used in research on non-small cell lung cancer. | Jun 09 2025 |
| E5952 | PT 3 | PT 3 is a benzamide-class, potent, and selective inhibitor of Histone Deacetylase 3 (HDAC3) with an IC50 of 245 nM. It crosses the blood-brain barrier and enhances learning and memory in novel object recognition models in mice. | May 29 2025 |
| E5974 | DDD85646 | DDD85646 (IMP-366) is an orally active inhibitor of N-myristoyltransferase(NMT), with an IC50 of 2 nM for Trypanosoma brucei NMT (TbNMT) and 4 nM for human NMT (hNMT). It exhibits a potential for treating human African trypanosomiasis. | May 28 2025 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| F3346 | A20/TNFAIP3 (J7N7) Rabbit mAb | Apr 17 2025 | |
| E5916 | RS47 | RS47 is a potent and specific inhibitor of the non-canonical NF-κB signaling pathway through disrupting RelB binding to its target DNA with a Kd values of 1.1 μM. It is shown to inhibit colorectal cancer (CRC) cells and B lymphoma growth, holds potential as a research tool for targeting cancers driven by hyperactive non-canonical NF-κB signaling. | Apr 09 2025 |
| F2879 | IKK β (K18H24) Rabbit mAb | Mar 03 2025 | |
| E4698 | Temoporfin | Temoporfin (m-THPC), a reduced porphyrin, is a potent second-generation photosensitizer. Temoporfin can be used in the research of photodynamic therapy (PDT) for head and neck cancers. | Dec 26 2024 |
| E7840 | EF24 | EF24, a synthetic analog of curcumin, is a potent antitumor agent that inhibits tumor growth and metastasis by blocking NF-κB-dependent signaling pathways. It also induces cell cycle arrest and apoptosis through a redox-dependent mechanism in MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells. | Dec 20 2024 |
| E7865 | MnTBAP chloride | MnTBAP chloride is a superoxide dismutase (SOD) mimetic and peroxynitrite scavenger. MnTBAP chloride is a manganic porphyrin complex and has anti-oxidative property. MnTBAP chloride mediates anti-inflammatory effects through upregulation of BMPR-II and inhibition of the NFκB signaling. MnTBAP chloride has the potential for the fibrotic response in chronic kidney diseases (CKDs) research. | Dec 20 2024 |
| E8130 | TAT-14 | TAT-14 is a 14-mer peptide that acts as Nrf2 activator with an anti-inflammatory effect. TAT-14 has no effect on Nrf2 mRNA expression, but increases Nrf2 protein level due to targeting the Nrf2 binding site on Keap1. | Dec 20 2024 |
| E1278 | ACHP Hydrochloride | ACHP Hydrochloride (IKK-2 Inhibitor VIII) is a highly potent and selective IKK-β inhibitor with an IC50 of 8.5 nM. | Dec 20 2024 |
| E7641 | TNF-α (31-45), human | TNF-α (31-45), human is a potent activator of NF-kB pathway. It is an inflammatory cytokine produced by macrophages/monocytes during acute inflammation and is responsible for a diverse range of signalling events within cells, leading to necrosis or apoptosis. It can be used in research of autoimmune diseases. | Dec 20 2024 |
| E2507 | BI605906 | BI605906 is a selective inhibitor of IKKβ with an IC50 of 380 nM when assayed at 0.1 mM ATP, suppressing the phosphorylation and activation of IKKβ, modulating NF-κB signalling. It also inhibits the insulin-like growth factor 1 (IGF1) receptor, with an IC50 of 7.6 μM. BI605906 effectively blocks TNF-α-dependent IκB degradation and reduces the expression of proinflammatory cytokines, including IL-6, IL-1β, and C-X-C motif ligands CXCL1/2. | Dec 20 2024 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| F4578 | Asparagine Synthetase Rabbit mAb | Jul 06 2025 | |
| E1027 | Voclosporin | Voclosporin is a potent, inhibitor of Calcineurin. It exhibits both immunomodulatory and non-immune effects by inhibiting T-cell proliferation, reducing proteinuria through podocyte cytoskeleton stabilization and afferent arteriole vasoconstriction, and effectively suppressing lymphocyte proliferation and cytokine production, making it useful for systemic lupus erythematosus (SLE) research. | Jun 24 2025 |
| F3127 | ATP5C1 Mouse mAb | Jun 16 2025 | |
| F3417 | GFPT2 Rabbit mAb | GFAT2,GFPT2 | Jun 16 2025 |
| E8291 | ABD0171 | ABD0171 is a potent, irreversible, and selective inhibitor of aldehyde dehydrogenase 1A3 (ALDH1A3), with an IC50 of 0.34 µM using the physiological substrate all-trans-retinaldehyde (atRAL). It also inhibits ALDH1A2 and ALDH1A1 with IC50 of 0.79 µM and 6.6 µM, respectively. ABD0171 disrupts key oncogenic pathways in triple-negative breast cancer (TNBC) cells in vitro and exhibits robust antitumor and antimetastatic activity in vivo. | Jun 09 2025 |
| E8300 | Amezalpat | Amezalpat is a first-in-class, oral, competitive antagonist of peroxisome proliferator-activated receptor α (PPARα), with IC50 of 0.04 µM. It inhibits fatty acid oxidation (FAO), disrupting cancer cell metabolism and restoring immune responses, and shows antitumor activity in research on advanced solid tumors. | Jun 09 2025 |
| E8281 | ATUX-1215 | ATUX-1215 is an orally bioavailable diarylmethyl-4-aminopyran sulfonamide that activates protein phosphatase 2A (PP2A) by stabilizing AC heterodimers and promoting heterotrimer formation with B subunits. It restores suppressed PP2A activity in IPF models, improving lung function, reducing collagen deposition, and downregulating fibrotic cytokines. ATUX-1215 also exhibits potent antifibrotic effects. | Jun 08 2025 |
| E8286 | Ivospemin | Ivospemin is a spermine analogue and polyamine inhibitor that lowers polyamine levels by inhibiting the activity of the polyamine biosynthetic enzyme ornithine decarboxylase (ODC) in cancer cell lines. It shows potential as a treatment for metastatic pancreatic adenocarcinoma. | Jun 08 2025 |
| E4705 | JAB-3312 | JAB-3312 is a potent allosteric inhibitor of SHP2 with an IC50 of 1.9 nM and a Kd of 0.37 nM. It is a potential anticancer agent and can be used in cancer research. | Jun 05 2025 |
| F3380 | xCT/SLC7A11 (H13H3) Rabbit mAb | xCT,xCT/SLC7A11 | May 27 2025 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| F3291 | CLPX Rabbit mAb | May 27 2025 | |
| S7395 | PD 150606 | PD150606 is a potent and selective inhibitor of calpainwith Ki values of 0.21 µM for µ-calpain and 0.37 µM for m-calpain. It exhibits neuroprotective effects by reducing hypoxic/hypoglycemic injury in cerebrocortical neurons and excitotoxic damage in cerebellar Purkinje cells. | Apr 14 2025 |
| F2430 | Neutrophil Elastase Rabbit mAb | Mar 03 2025 | |
| F2761 | PCSK9 (F3K11) Rabbit mAb | Mar 03 2025 | |
| E5835 | Heparin | Heparin is a highly sulfated polysaccharide primarily used as an anticoagulant, which works mainly by inhibiting thrombin (FIIa) and/or factor Xa (FXa). It is commonly used to prevent and treat thromboembolic conditions such as deep vein thrombosis and pulmonary embolism. It also plays roles in inflammation, angiogenesis, and growth factor signaling, with potential therapeutic applications in cancer treatment and allergic conditions. | Feb 10 2025 |
| E6045 | 2'-C-Methylcytidine | 2'-C-Methylcytidine (NM107) is a potent and selective inhibitor of Chronic hepatitis C virus (HCV) NS5B polymerase with an EC50 of 1.85 μM in wild-type replicon cells. It also effectively inhibits foot-and-mouth disease virus(FMDV) replication with an EC50 of 6.4 μM. Therefore it is a potent antiviral that targets both viral and host factors, making it a promising option for HCV therapy and a potential prophylactic or therapeutic agent against FMDV outbreaks. | Jan 20 2025 |
| E6002 | Ledipasvir D-tartrate | Ledipasvir D-tartrate (GS-5885 D-tartrate), the D-tartrate salt form of ledipasvir, is an inhibitor of the HCV NS5A, which is essential for the replication of the virus. It exhibits EC50 of 31 pM against GT1a and 4 pM against GT1b replicons. | Dec 22 2024 |
| E7848 | Otamixaban | Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.IC50 value:Target: Factor Xa Otamixaban is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa. In vivo experiments have demonstrated that Otamixaban is highly efficacious in rodent, canine and porcine models of thrombosis. In addition, recent clinical findings indicate that Otamixaban is efficacious, safe and well tolerated in humans and therefore has considerable potential for the treatment of acute coronary syndrome. This review article chronicles the discovery a | Dec 20 2024 |
| E7851 | GSK2256294A | GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH). GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC50s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease. | Dec 20 2024 |
| E7611 | HET0016 | HET0016 is a potent and selective 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor, with IC50 values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis, respectively. HET0016 also is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth. | Dec 20 2024 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| F2598 | TMPRSS2 Rabbit mAb | Jun 25 2025 | |
| E8298 | Duocarmycin SA | Duocarmycin SA is a potent antitumor antibiotic with an IC50 of 10 pM. It is an extremely potent cytotoxic agent capable of inducing a sequence-selective alkylation of duplex DNA and can be used in research treatment for glioblastoma multiforme (GBM). | Jun 08 2025 |
| E6075 | Penicillin G benzathine tetrahydrate | Penicillin G benzathine tetrahydrate (Benzathine benzylpenicillin tetrahydrate) is a long-acting beta-lactam antibiotic effective against many bacterial infections such as impetigo. | May 28 2025 |
| E6061 | Cefamandole sodium | Cefamandole (sodium) is a parenteral, broad-spectrum, second-generation cephalosporin antibiotic effective against various gram-positive and gram-negative bacteria, including Neisseria, Haemophilus, and Proteus species. | May 22 2025 |
| E6063 | sulphaquinoxaline | Sulfaquinoxaline (Sulfaquinoxaline) is a sulfonamide antimicrobial used in veterinary medicine to prevent and treat coccidiosis and bacterial infections. It is effective against a broad range of Gram-positive and Gram-negative bacteria. | Apr 13 2025 |
| E6052 | Enrofloxacin hydrochloride | Enrofloxacin hydrochloride is a fluoroquinolone antibiotic with potent activity against Mycoplasma bovis, showing an MIC₉₀ of 0.312 μg/mL. It can be used in research to study treatments for pneumonia, mastitis, arthritis, and other conditions in cattle. | Apr 11 2025 |
| E8272 | Dihydroarteannuin B | Dihydroarteannuin B is a cadinane sesquiterpene isolated from the dried leaves of Artemisia annua acts as a microbial metabolite of arteannuin B. It can be used in research for developing malaria treatments. | Mar 17 2025 |
| E1422 | (+)-JNJ-A07 | (+)-JNJ-A07 is a highly potent inhibitor of Dengue virus (DENV) with an EC50 of 0.1 nM in the DENV-2 strain (16681) in Vero cells. It exhibits antiviral activity by preventing the formation of the viral replication complex through blocking the interaction between two viral proteins, NS3 and NS4B. | Jan 16 2025 |
| E4996 | Puromycin | Puromycin (CL13900, Puromycine) is an antibiotic, analog of the 3' end of aminoacyl-tRNA and an inhibitor of protein synthesis that mimics tyrosyl-tRNA, causing premature termination of translation. It blocks translation by labeling and releasing elongating polypeptide chains from ribosomes and has been widely used in molecular biology research. | Dec 26 2024 |
| E8153 | Filipin complex | Filipin complex is a potent polyene macrolide antifungal antibiotic that integrates into membranes, sequestering cholesterol into complexes. Its treatment reduces PRRSV genome copies by 61% and lowers the PRRSV titer. It also acts as a fluorescent histochemical stain prone to autooxidation, commonly used in diagnosing Niemann-Pick Disease Type C (NP-C), a neurodegenerative lysosomal storage disorder. Researchers also employ it to study unesterified cholesterol distribution in cell and animal models of neurodegenerative diseases like NP-C and Sanfilippo syndrome (MPS IIIA). | Dec 26 2024 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| F3261 | cIAP1 Rabbit mAb | cIAP1,c-IAP1 | Jun 25 2025 |
| F2849 | Survivin (C6B16) Rabbit mAb | Jun 16 2025 | |
| E8278 | WH244 | WH244 is a second-generation PROTAC that selectively degrades the anti-apoptotic proteins BCL-xL and BCL-2 with a DC50 of 0.6 nM for BCL-xL and 7.4 nM for BCL-2. | Jun 08 2025 |
| E8289 | dTAGV-1 TFA | dTAGV-1 TFA is a potent and selective degrader that recruits the VHL E3 ligase to selectively degrade FKBP12F36V-tagged proteins. It enables rapid degradation of oncogenic proteins such as KRASG12V and EWS/FLI, demonstrating significant antitumor efficacy both in vitro and in vivo. | Jun 08 2025 |
| F3303 | Bag1 Rabbit mAb | May 27 2025 | |
| E5910 | KRAS-533 | KRAS-533 is a potent agonist of KRAS that binds to the GTP/GDP-binding pocket and prevents the hydrolysis of GTP, leading to accumulation of active GTP-bound KRAS. This triggers both apoptotic and autophagic cell death pathways in cancer cells, leading to potent suppression of mutant KRAS lung cancer in vitro and in animal models. | May 20 2025 |
| F1568 | GSDMD Rabbit mAb | Gasdermin D,GSDMD,GSDMDC1 | Apr 17 2025 |
| F3373 | GATA3 Rabbit mAb | GATA3,Gata-3 | Apr 17 2025 |
| F2366 | Phospho-p53 (Ser 37) Rabbit mAb | p53 (phospho S37),Phospho-p53 (Ser37),TP53 (phospho S37) | Apr 01 2025 |
| F2855 | Bim (P2D10) Rabbit mAb | Mar 27 2025 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| E8290 | Flezurafenib | Flezurafenib is an oral inhibitor of pan-RAF with potential antineoplastic activity. | Jun 09 2025 |
| E4690 | Gingerenone A | Gingerenone A is a a polyphenol present in ginger, an inhibitor of p70 S6 (S6K1) and an activator of Nrf2-Gpx4 signaling pathway to alleviate ferroptosis in secondary liver injury in colitis. It exhibits anti-adipogenic, anti-lipogenic, anti-hyperglycemic, anti-obesity, and anti-inflammatory effects, and holds promise for research into anti-diabetic and anti-obesity drug development. | May 20 2025 |
| E5898 | SKLB-D18 | SKLB-D18 is a first-in-class, potent, and selective inhibitor of ERK1/2 and ERK5 with an IC50's of 38.69 nM, 40.12 nM, and 59.72 nM, respectively, that also acts as an agonist of autophagy. It modulates mTOR/p70S6K and NCOA4-mediated ferroptosis, showing strong anti-tumor activity and offering a promising monotherapy strategy to overcome resistance in ERK1/2-targeted therapy for triple-negative breast cancer (TNBC). | May 20 2025 |
| E1943 | Tunlametinib | Tunlametinib (HL-085) is a highly selective and oral inhibitor of MEK1/2 with an IC50 of 1.9 nM for MEK1, with the potential to treat RAS/RAF mutant cancers. It also induces cell cycle arrest at the G0/G1 phase and promotes apoptosis in a dose-dependent manner. It also exhibits antitumor activity in patients with advanced NRAS-mutant melanoma. | May 08 2025 |
| E5816 | PF-07265028 | PF-07265028 is a potent and selective inhibitor of hematopoietic progenitor kinase 1 (HPK1/MAP4K1) with a Ki of <0.05 nM, and exhibits potent cellular activity, with a pSLP76 IC50 of 17 nM. | May 08 2025 |
| F2533 | JNK2 (L14H21) Rabbit mAb | Apr 29 2025 | |
| E4726 | NDI-101150 | NDI-101150 is a potent HPK1 (MAP4K1) inhibitor that selectively activates immune cells such as T cells, B cells, and dendritic cells. It significantly inhibits tumor growth and induces complete tumor regression in the EMT-6 mouse model. | Mar 26 2025 |
| E1938 | HRX215 | HRX215 (Darizmetinib) is a first-in-class, highly potent, selective, and orally active inhibitor of MKK4 with an IC50 of 0.02 µM. It enhances liver regeneration, prevents liver failure following extensive hepatectomy in pigs, and has potential to prevent liver failure after major oncological liver resections or transplantation of small liver grafts in humans. | Mar 10 2025 |
| F2830 | Phospho-ATF2 (Thr 71) Rabbit mAb | Mar 03 2025 | |
| F2944 | Phospho-ATF1 (Ser 63) Rabbit mAb | Mar 03 2025 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| F3240 | PDGFR α Rabbit mAb | PDGF Receptor alpha/PDGFR-α,PDGF Receptor α,PDGFR alpha | May 27 2025 |
| A4039 | Yh32367 (Anti-4-1BB & HER2) | Yh32367 is a humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9). It exhibits potential immunostimulating and antineoplastic activities. M.W 200.52 kDa. | Mar 09 2025 |
| A4042 | Ibi-334 (Anti-B7-H3 & EGFR) | Ibi-334 is an ADCC-enhanced bispecific antibody targeting B7-H3 and EGFR, showing potent preclinical efficacy in solid tumors. It blocks EGFR signaling while utilizing a finely tuned B7-H3 arm to enhance inhibition. M.W 145.58 kDa. | Mar 09 2025 |
| A4048 | Afm24 (Anti-EGFR & Fc-gamma-RIIIA) | Afm24 is a human, tetravalent bispecific antibody targeting EGFR on tumor cells and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A) on innate immune cells. It enhances NK cell-mediated cytotoxicity and macrophage-driven phagocytosis, making it a promising immunotherapy with reduced EGFR-related toxicities for cancer treatment. M.W 196.34 kDa. | Mar 09 2025 |
| A4052 | Faricimab (Anti-Angiopoietin 2 & VEGF-A) | Faricimab is a humanized bispecific antibody that targets vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2; Ang2; ANGPT2), key regulators of vascular leakage and inflammation. It is used to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion, improving retinal vascular stability. M.W 146.41 kDa | Mar 09 2025 |
| F2970 | AMF mAb | AMF,GPI | Jan 21 2025 |
| F2527 | VEGFA Rabbit mAb | Dec 31 2024 | |
| F1068 | VE-cadherin Mouse mAb | Dec 31 2024 | |
| F1087 | HIF-2α mAb | EPAS1,EPAS-1/HIF-2 alpha,HIF-2 alpha/EPAS1,HIF-2-alpha,HIF-2α | Dec 17 2024 |
| F0906 | Phospho-Src (Ser 17) Rabbit mAb | Nov 14 2024 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| E6426 | Sulindac sulfide | Sulindac sulfide is a potent, reversible and noncompetitive inhibitor of γ42-secretase with an IC50 of 20.2 μM. It preferentially reduces Aβ42 generation, inhibits Aβ40 and Notch intracellular domain production, and can be used in Alzheimer's disease research. | Jun 16 2025 |
| F0104 | Oct4 Rabbit mAb | Oct3/4,Oct-3/4,Oct4,Oct-4,OCT-4 [POU5F1] | May 27 2025 |
| E6057 | Pamidronate disodium pentahydrate | Pamidronate disodium pentahydrate is a nitrogen-containing bisphosphonate and used to prevent bone loss due to steroid use like glucocorticoid-induced low bone mineral density in children or to inhibit calcium release from bone by impairing osteoclast-mediated bone resorption. It also inhibits the Wnt/β-catenin signaling pathway that controls osteogenic differentiation in bone marrow mesenchymal stem cells (BMMSCs). | May 15 2025 |
| F2646 | Dab2 Rabbit mAb | Apr 29 2025 | |
| F2817 | Zic2 Rabbit mAb | Mar 27 2025 | |
| F2873 | Nanog (H17H16) Rabbit mAb | Mar 27 2025 | |
| F3068 | Oct-4A Rabbit mAb | Mar 03 2025 | |
| F2778 | Myf5 Rabbit mAb | Mar 03 2025 | |
| F3232 | LEF1 (B21M20) Rabbit mAb | Mar 03 2025 | |
| F3408 | Wnt16 Rabbit mAb | Mar 03 2025 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| F2498 | USP11 Rabbit mAb | Jun 25 2025 | |
| E5999 | CT1113 | CT1113 is a potent dual inhibitor of USP25 and USP28 that effectively reduces c-MYC levels and exhibits strong anti-tumor activity. It can be used in research on colon and pancreatic cancers. | Jun 16 2025 |
| E5877 | LYG-409 | LYG-409 is a potent, selective, and orally bioavailable degrader of GSPT1, with a DC50 of 7.87 nM. It exhibits strong antiproliferative activity in KG-1 cells with an IC50 of 9.50 nM and demonstrates significant antitumor efficacy in vivo in models of acute myeloid leukemia and prostate cancer. | May 22 2025 |
| E5945 | Wu-5 | Wu-5 is an inhibitor of USP10 that blocks its activity in vitro with an IC50 of 8.3 µM. It also promotes FLT3-ITD degradation and synergistically enhances crenolanib-induced apoptosis. | Apr 20 2025 |
| E5839 | OICR-8268 | OICR-8268 is a potent, reversible and in-cell active DCAF1 ligand. It significantly binds to DCAF1 WDR domain with an Kd value of 38 nM. It serves as a promising starting point for developing chemical handles for DCAF1-based PROTACs targeting selective protein degradation as well as cancer therapeutics. | Apr 01 2025 |
| F2526 | MDM2 mAb | Mar 30 2025 | |
| F1464 | NEDD4 Rabbit mAb | Mar 30 2025 | |
| E5771 | BIO-2007817 | BIO-2007817 is a tetrahydropyrazolo-pyrazine and a positive allosteric modulator(PAM) that can act as a molecular glue to enhance the ability of pUb to activate Parkin with an EC50 of 150 nM. It can be used in research design of activators as therapeutics for Parkinson’s disease. | Mar 30 2025 |
| F2924 | Cullin 2/CUL-2 Rabbit mAb | Mar 27 2025 | |
| F1118 | UBE2I / UBC9 Rabbit mAb | Mar 03 2025 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| E8311 | Isoprenaline | Isoprenaline is a synthetic, non-selective agonist of beta-adrenergic receptor and is used for the treatment of bradycardia, heart block, and congestive heart failure. | Jul 04 2025 |
| F4580 | COMT Rabbit mAb | Jul 03 2025 | |
| P1255 | Jagged-1 (188-204) (TFA) | Jagged-1 (188-204) (TFA) is a peptide fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity. JAG-1 is highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 also induces the maturation of monocyte-derived human dendritic cells. | Jun 18 2025 |
| E5930 | REM127 | REM127 is a small molecule that restores calcium homeostasis by stabilizing the septin cytoskeleton, thereby preventing pathological calcium influx in models of tauopathies. It improves synaptic plasticity, reduces tau and Aβ pathology, and rescues memory function in disease models. It exhibits a potential for treating Alzheimer’s disease and frontotemporal dementia. | Jun 09 2025 |
| E6066 | cyproheptadine | Cyproheptadine is a potent and orally active antagonist of 5-HT2A receptor with antiserotonergic and antidepressant effects. It also exhibits antiplatelet activities and has the potential to treat thromboembolic and depressive disorders. | May 28 2025 |
| E6068 | levosalbutamol hydrochloride | levosalbutamol hydrochloride ((R)-Salbutamol hydrochloride, (R)-Salbutamol hydrochloride) is a short-acting agonist of the β2 adrenergic receptor used to treat asthma and chronic obstructive pulmonary disease (COPD). It is the active (R)-enantiomer of salbutamol. | May 22 2025 |
| E6048 | (S)-Terazosin | (S)-Terazosin is a potent and selective antagonist of α-adrenoceptor with Ki values of 3.91 nM, 0.79 nM and 1.16 nM for α1a, α1b and α1d-adrenoceptor, respectively. It also has high-affinity for α2a, α2B and α2c-adrenoceptor with Ki values of 729 nM, 3.5 nM and 46.4 nM, respectively. It may prove to be a useful probe in understanding the functional role of subtypes of adrenoceptors in various tissues. | May 20 2025 |
| E5913 | LXG6403 | LXG6403 is a bi-thiazole potent inhibitor of LOX cellular activity with an IC50 of 1.3 μM. It exhibits anti-cancer activity by remodeling the extracellular matrix, enhancing chemotherapy penetration, inducing ROS generation, and promoting DNA damage-mediated cell death to overcome chemotherapy resistance in triple-negative breast cancer. | Apr 22 2025 |
| E6060 | BUSPIRONE | BUSPIRONE (Ansial) is a potent agonist of serotonin 5-HT1A receptor as well as an antagonist of dopamine D2 autoreceptor. It exhibits anxiolytic and antidepressant activity, alleviates anxiety, depression, and colitis, suppresses neuroinflammation, modulates gut microbiota, and can be used in research for treating anxiety and depression. | Apr 22 2025 |
| E6056 | (R)-tamsulosin | (R)-Tamsulosin ((R)-(-)-YM12617 free base, LY253351 free base) is the enantiomerically pure, pharmacologically active form of tamsulosin, a selective α₁A-adrenergic receptor antagonist used in the treatment of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). This form is synthesized using chiral N-(1-phenylethyl)aziridine-2-carboxylate derivatives, which allow for highly stereoselective processes in its production. | Apr 15 2025 |
| Catalog No. | Product Name | Information | Added |
|---|---|---|---|
| S9966 | SAFit2 | Jul 08 2025 | |
| F3506 | DYKDDDDK Tag Rabbit mAb | DDDDK tag (Binds to FLAG tag sequence),DYKDDDDK (FLAG(R) epitope tag),DYKDDDDK Epitope Tag,DYKDDDDK Tag,FLAG,Flag tag,FLAG(R),FLAG(R) M2,OctA-Probe | Jul 08 2025 |
| E5874 | INT-767 | Jul 08 2025 | |
| E6461 | Cholesteryl hemisuccinate | Jul 06 2025 | |
| E5880 | Necrocide1 | Necrocide1 is a potent inducer of cancer cell necrosis and displays antiproliferative activity with IC50 values of 0.48 nM and 2 nM for MCF-7 and PC3 cells, respectively. Necrocide1 also exerts potent antitumor effects in xenograft models. | Jul 01 2025 |
| E5990 | Biotin-HPDP | Biotin-HPDP is a thiol-specific biotinylating reagent that forms a reversible disulfide bond with free cysteine residues on proteins or peptides. It is widely used to selectively tag and detect sulfhydryl groups, especially in biochemical assays. In the Biotin Switch assay, Biotin-HPDP labels newly exposed cysteine thiols after reduction of S-nitrosylated or S-sulfhydrated proteins, enabling detection and purification via streptavidin-based methods. | Jun 27 2025 |
| F3208 | Nova1 Rabbit mAb | Jun 25 2025 | |
| E6402 | GSK4418959 | GSK4418959 is a non-covalent, reversible, selective and orally active inhibitor of WRN helicase. It inhibits ATPase and DNA unwinding functions in an ATP-competitive manner and can be a potential therapeutic agent that can be used for the study of microsatellite instability-high (MSI-H) cancer research. | Jun 16 2025 |
| E6404 | BMS-986449 | BMS-986449 is a CELMoD molecular glue and a degrader of IKZF2/IKZF4. It redirects the E3 ubiquitin ligase Cereblon to induce the degradation of Helios and Eos in Treg cells, to enhance antitumor immunity, and shows promise for advanced solid tumor research. | Jun 16 2025 |
| F2763 | NgBR Rabbit mAb | Jun 16 2025 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.